IIC
WST icon

Integrated Investment Consultants’s West Pharmaceutical WST Stock Holding History

Integrated Investment Consultants’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Hold
924
– – 0.07% 189
2026
Q1 		$232K Buy
924
+1
+0.1% +$249 0.05% 236
2025
Q4 		$254K Sell
923
-22
-2% -$6.02K 0.05% 230
2025
Q3 		$248K Hold
945
– – 0.04% 283
2025
Q2 		$207K Hold
945
– – 0.04% 305
2025
Q1 		$212K Sell
945
-2
-0.2% -$551 0.04% 303
2024
Q4 		$310K Hold
947
– – 0.06% 226
2024
Q3 		$284K Sell
947
-10
-1% -$3.06K 0.06% 242
2024
Q2 		$379K Hold
957
– – 0.1% 170
2024
Q1 		$379K Sell
957
-6
-0.6% -$2.22K 0.1% 170
2023
Q4 		$339K Buy
963
+2
+0.2% +$708 0.11% 170
2023
Q3 		$361K Sell
961
-16
-2% -$6.19K 0.13% 138
2023
Q2 		$374K Sell
977
-9
-0.9% -$3.21K 0.12% 152
2023
Q1 		$342K Buy
986
+11
+1% +$3.21K 0.11% 171
2022
Q4 		$229K Buy
975
+13
+1% +$3.08K 0.08% 214
2022
Q3 		$237K Sell
962
-4
-0.4% -$1.22K 0.09% 185
2022
Q2 		$292K Hold
966
– – 0.11% 163
2022
Q1 		$397K Sell
966
-26
-3% -$10.2K 0.11% 171
2021
Q4 		$465K Buy
992
+5
+0.5% +$2.15K 0.12% 144
2021
Q3 		$419K Buy
987
+13
+1% +$5.48K 0.12% 154
2021
Q2 		$350K Hold
974
– – 0.1% 191
2021
Q1 		$274K Hold
974
– – 0.09% 197
2020
Q4 		$276K Hold
974
– – 0.1% 185
2020
Q3 		$268K Sell
974
-254
-21% -$67.2K 0.13% 146
2020
Q2 		$279K Buy
+1,228
New +$241K 0.13% 115
2018
Q4 		– Sell
-1,916
Closed -$237K – 187
2018
Q3 		$237K Buy
+1,916
New +$215K 0.12% 139
2018
Q2 		– Sell
-1,565
Closed -$138K – 712
2018
Q1 		$138K Buy
+1,565
New +$146K 0.05% 251
2017
Q3 		$108K Buy
1,123
+270
+32% +$24.4K 0.05% 281
2017
Q2 		$81K Buy
+853
New +$78.5K 0.04% 331

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Integrated Investment Consultants's WST Position: Q2 2026 in Review

Integrated Investment Consultants held its West Pharmaceutical (WST) position steady in Q2 2026 at 924 shares worth $332K. The position accounts for 0.07% of the portfolio, ranked #189.

Integrated Investment Consultants first reported a position in WST in Q2 2017 and has held it in 29 quarters since. The position peaked at $465K in Q4 2021. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Integrated Investment Consultants held 924 shares of West Pharmaceutical worth $332K as of Q2 2026.
  • Integrated Investment Consultants left its West Pharmaceutical share count unchanged in Q2 2026.
  • West Pharmaceutical made up 0.07% of Integrated Investment Consultants's portfolio in Q2 2026, its #189 holding.
  • Integrated Investment Consultants first reported a position in West Pharmaceutical in Q2 2017 and has held it in 29 quarters since.
  • Integrated Investment Consultants's West Pharmaceutical position peaked at $465K in Q4 2021.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Integrated Investment Consultants's 13F filing for Q2 2026, filed 17 Aug 2026.